
Breakthrough: FDA Approves Oral Treatment for Postpartum Depression
The FDA has approved Zurzuvae (zuranolone), the first oral medication for postpartum depression (PPD) in adults. PPD is a major depressive episode that occurs after childbirth or during late pregnancy. Previously, treatment for PPD was only available as an IV injection. Zurzuvae demonstrated efficacy in two studies, showing significant improvement in depressive symptoms compared to placebo. However, the medication carries a boxed warning regarding its impact on driving and other potentially hazardous activities. Common side effects include drowsiness, dizziness, diarrhea, fatigue, and urinary tract infection. Zurzuvae may cause fetal harm, and effective contraception is recommended while taking the medication.
